Micronized API High-Shear Wet Granulation for 10 mg Immediate-Release Tablets

In tablet applications the API is used at a nominal 10 mg dose. Ezetimibe is practically insoluble in water. Biopharmaceutical release from an immediate-release tablet is controlled by specific surface area and wettability. Air-jet milling is used to reduce primary particles. The milled API is characterized by laser diffraction per USP <429>. Surface area can be cross-checked by gas adsorption. High-shear wet granulation becomes necessary when direct compression of the micronized API produces cohesive agglomerates and poor flow. The process starts with a pre-blend of ezetimibe, lactose monohydrate, and croscarmellose sodium. A purified-water binder solution containing povidone K29/32 is added at a defined rate. Impeller speed and chopper speed are adjusted based on mass consistency. End-point control on a production granulator is commonly monitored by impeller power draw rather than fixed time. In full-scale equipment, batch-to-batch variance arises from differences in granulator bowl loading, water addition rate, and spray nozzle pattern. After granulation the wet mass is milled through a 2 mm screen. Drying is performed in a fluid-bed dryer with inlet air temperature controlled to avoid binder migration. The dried granule target is below 2.0% w/w loss on drying by USP <731>. Final milling through a conical mill screen produces granules with low fines and acceptable flow.

Tablet compression on a rotary press is run with pre-compression and main compression stations. The compression force is determined within a design space based on tablet breaking force per USP <1217>. Friability at the design force is expected to meet USP <1216> with a limit of not more than 1.0% after 100 rotations. The in-process controls include weight, hardness, thickness, disintegration, and visual inspection. 21 CFR 211.110 requires written in-process specifications. Dissolution testing per USP <711> uses a surfactant-containing medium to maintain sink conditions because of low aqueous solubility. Published data for ezetimibe-specific dissolution performance in a fixed composition are limited. A design-of-experiments approach is appropriate for varying binder level, disintegrant level, and drying endpoint.

What Limits Content Uniformity When Ezetimibe Is Blended at 3.3% Drug Load?

Low drug load is the primary control problem when a 10 mg dose is distributed in a 300 mg tablet core. The drug load is 3.3% w/w. This low drug load makes the blend sensitive to segregation at every transfer step. Micronized ezetimibe exhibits cohesion and electrostatic adhesion. The API may stick to stainless-steel surfaces, polyethylene liners, and discharge chutes. A pre-blend of API with lactose monohydrate is passed through a 500 µm sieve. The pre-blend is then charged into a V-blender or bin blender. Fill volume is kept between 40% and 70% of vessel capacity to promote shear and reduce dead zones. Unit-dose uniformity is assessed per USP <905>. An acceptance value ≤ 15.0 is required. Powder blend samples are tested for relative standard deviation. Full-scale trials should demonstrate blend RSD ≤ 5.0% to provide capability for a passing acceptance value. Published data for ezetimibe-specific blend RSD are limited. The addition of 0.5% w/w colloidal silicon dioxide may be needed. Magnesium stearate is added last at 0.5–1.0% w/w. Over-lubrication reduces tablet tensile strength and slows dissolution. Lubricant blending time is controlled between 3 and 5 minutes after final pre-blend. The final blend is transferred under low humidity. In-process sampling follows 21 CFR 211.110.

Capsule filling at 10 mg nominal dose introduces a different segregation mechanism than tablet compression. The powder is filled into hard gelatin or HPMC capsules on a dosator or tamping-pin automatic encapsulator. Micronized ezetimibe can accumulate on filling machine surfaces and alter flow. Fill weight control for low-fill-weight capsules is typically run with a 120 mg to 200 mg powder range for a size 3 shell. The blend is monitored before and during the run for compressibility index per USP <616>. Content uniformity of sealed capsules is evaluated per USP <905>. Dissolution is tested per USP <711> with capsule shell rupture as a separate variable. The processing environment is controlled at 45–55% relative humidity. Gelatin cross-linking can occur at higher humidity and temperature. HPMC shells are selected when moisture-sensitive formulations cannot tolerate high-humidity storage. Blend segregation in the hopper remains the main process failure mode. Full-scale encapsulator runs above 30,000 capsules per hour may require forced feeding. Published data for ezetimibe capsule-specific speeds are limited. The use of 0.5% w/w colloidal silicon dioxide and 0.75% w/w magnesium stearate is a common low-dose starting point. Filled capsules are checked for weight variation, disintegration per USP <701>, and dissolution per USP <711>. The absence of a wet granulation step means the crystalline API must already be micronized to an appropriate particle size.

Statin Co-Formulation Degradation Pathways and Dry Granulation Boundaries

Ezetimibe is co-formulated with simvastatin or atorvastatin calcium in fixed-dose combinations. Commercial strength combinations include ezetimibe/simvastatin at 10/10, 10/20, 10/40, and 10/80 mg. The co-formulation is more complex than ezetimibe alone because the statin component carries additional degradation liabilities. Simvastatin is a lactone prodrug. Acid-catalysed hydrolysis can open the lactone ring in the presence of excess moisture and heat. Atorvastatin calcium is sensitive to humidity. In atorvastatin calcium formulations, an alkaline microenvironment has been described in published formulation work. These degradation pathways influence the selection of dry granulation or direct compression over aqueous wet granulation. If aqueous granulation is used, water exposure time and drying temperature must be minimized. Published data for ezetimibe/statin-specific formulation conditions are limited. The general process boundary is low moisture, low thermal load, and controlled compression force.

Roller compaction is often selected when a densified granule is necessary. Ribbon density is controlled by roll pressure, roll speed, and gap. Milling of the compacted ribbon through a 0.8 mm screen produces granules with a bimodal size distribution. The granule fraction below 75 µm contributes to die fill and content uniformity. Tablet compression uses a multi-layer or monolithic rotary press. Breaking force is set to a range that avoids capping while maintaining acceptable disintegration. Dissolution testing of both active components is required at multiple time points. A similarity factor f2 ≥ 50 against a reference product is used for comparison. The fixed-dose combination is packaged in moisture-protective containers. Stability testing under 21 CFR 211.166 and ICH Q1A(R2) conditions is required. Container closure systems are selected based on moisture vapour transmission rate and desiccant weight.

Fluid-bed spray granulation is used when the target presentation is a unit-dose sachet or a reconstitutable oral suspension. A 10 mg ezetimibe dose is dispersed in a granule matrix of lactose monohydrate, mannitol, or microcrystalline cellulose. The binder solution is sprayed from a top-spray or bottom-spray nozzle onto fluidized powder. Inlet air temperature is maintained between 50°C and 70°C to avoid thermal degradation. Spray rate is balanced against inlet air moisture capacity. The granule endpoint is controlled by product temperature and exhaust humidity. Granules are dried to below 2.0% w/w loss on drying per USP <731>. Particle size is measured by sieve analysis per USP <786>. A target D50 between 150 µm and 250 µm generally provides acceptable flow and dispersion. Published data for ezetimibe-specific granule size are limited. The final granules are filled into sachet packs. Fill weight is adjusted to provide 10 mg ezetimibe per sachet. Typical fill weights are 1 g to 2 g depending on granule density and excipient load. Sachet filling requires gravimetric control because granule density variation directly changes delivered dose. The packed granule is tested for uniformity of mass, moisture, dissolution per USP <711>, and microbial limits per USP <61> and USP <62>. For reconstitutable suspensions, the granule may include a preservative such as sodium benzoate at the lowest effective concentration. The suspension is prepared with purified water. Physical stability of the reconstituted suspension should be evaluated over the intended in-use period. Published stability data for ezetimibe oral suspension are limited.

When Ezetimibe Is Processed into a Sterile Nanosuspension

No parenteral ezetimibe product is currently established in major pharmacopoeias. Published literature describes nanosuspensions, liposomal dispersions, and cyclodextrin inclusion complexes as investigational formulations. The fundamental challenge is the extremely low aqueous solubility of ezetimibe. For an injectable presentation, the API must be particle size-reduced or dissolved in a pharmaceutically acceptable solvent system. High-pressure homogenization is the most frequently reported top-down process. The pre-suspension is processed through a high-pressure homogenizer at 1000–1500 bar for multiple cycles. The resulting particle size is measured by dynamic light scattering per ISO 22412:2017 and laser diffraction per USP <429>. A target mean particle size below 200 nm is common for sterile nanosuspensions to avoid capillary blockage. The formulation must be isotonic and pH-compatible with parenteral administration. Parenteral products require bacterial endotoxin testing per USP <85>. Sterility is verified by membrane filtration per USP <71>. Particulate matter is controlled per USP <788>. Visible particulates are controlled per USP <790>. Terminal sterilization may be limited by API thermal stability. Aseptic filtration of nanosuspensions is difficult at larger particle sizes. Lyophilization with a cryoprotectant such as mannitol or trehalose may be required. The sterility assurance level is 1 × 10^-6 per pharmacopoeial expectation. Published data for this specific configuration are limited. Injectable ezetimibe remains an investigational route. Development batches require full characterization of particle size, zeta potential, osmolality per USP <785>, and pH. Cleaning validation for production equipment follows 21 CFR 211.67.